



Day 1 Jun 5	<i>All time are Pacific Daylight Time</i>	
8:00 am	Opening Comments and Pre-Test	Horwitz
8:15 am	Viral Hepatitis, Discovery of HCV and Its Natural History <ul style="list-style-type: none"> The evolving epidemiology of viral hepatitis around the world Manifestations of HCV and its relationship to HIV 	Gutierrez
9:00 am	Hepatitis C: Update on Diagnostics <ul style="list-style-type: none"> Screening and diagnostic approaches by cohort Liver biopsy and newer, non-invasive diagnostic tools Hepatitis C: Update on Treatment <ul style="list-style-type: none"> 2020 AASLD/IDSA Guidelines Simplified Guidance 	Gutierrez
10:00 am	Break and Product Theatre I	
10:45 am	Hepatitis B: Epidemiology, Natural History and Testing <ul style="list-style-type: none"> The epidemiology of the Hepatitis B infection Efficacies and opportunities in HBV testing and vaccination The growing relationship between HBV and HDV 	Vargas
11:15 am	Anti-viral Therapies for HBV <ul style="list-style-type: none"> Early detection and treatment approaches Treating HCC in patients with Hepatitis B Guidance statements for co-infected patients Agents to guard against reactivation 	Vargas
12:15pm	<i>Day 1 concludes</i>	
Day 2 Jun 12	Delta Hepatitis and HEV Update from AASLD <ul style="list-style-type: none"> Worldwide perspective on Hepatitis and promising research studies Real world outcome studies on DAA's 	Pockros
8:00 am	Case Studies 1 and 2 –HIV/HCV Co-infection and Infections in persons who inject drugs	
8:30 am	Viral Hepatitis Updates <ul style="list-style-type: none"> The reemergence of Hepatitis A Alcoholic liver disease Emerging prevention and treatment approaches 	Cave
9:00 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant <ul style="list-style-type: none"> Staging, workup, and diagnosis of cirrhosis Medical care of the patient with end stage liver disease Liver Transplantation <ul style="list-style-type: none"> Listing criteria, MELD scores, Exceptions and the transplant process Case Study 3– Cirrhosis and Encephalopathy	Fontana
9:45 am	Break and Product Theatre II	
10:30 am	SARS-CoV-2 in Liver Disease <ul style="list-style-type: none"> Effect of COVID on the liver and in cirrhotic patients COVID-19 challenges for liver transplant recipients 	Gutierrez
11:00 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> Screening diagnostic serum assays and imaging tests Diagnosis without histology Treatment and management options: Ablation, TACE and Surgery 	Frenette
11:30 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> Current FDA-Approved Therapies New chemotherapy regimens in development and testing 	Frenette



	<ul style="list-style-type: none"> Immunotherapy as the new MoA for HCC Case Study 4 – Diagnosis and Treatment of Hepatocellular Carcinoma	
12:15 pm	Day 2 concludes	
Day 3 Jun 19 8:00 am	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis <ul style="list-style-type: none"> Epidemiology of PSC and Ursodiol and Antibiotic Treatments Predicting outcomes and Improving Survival in PSC patients Causes and Markers of PBC Ursodeoxycholic Acid (UDCA) and Obeticholic Acid AASLD Update on Therapies 	Pockros
8:50 am	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> Epidemiology, Demographics and Diagnosis Scoring and Management of Fatty Liver Disease Raising awareness of LAL-D to avoid confusing symptoms with fatty liver disease Staging and Management 	Nourredin
9:40 am	Break and Product Theatre III	
10:25 am	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> Current therapies for NASH Lifestyle changes as a therapy Drugs in clinical development for NASH 	Nourredin
11:30 am	Closing Comments, Post-test and Wrap-Up	Paul Pockros
12:00 pm	Seminar adjourns	

Course Directors: Paul J. Pockros, MD - Scripps Clinic
Catherine Frenette, MD – Scripps Center for Cell and Organ Transplantation